Company intelligence / Profile preview

Intec Pharma Ltd.

Ownership: Private
Development stage: Phase 3

Overview

Intec Pharma developed the Accordion Pill®, an oral drug delivery system designed to improve efficacy and safety of existing drugs by enhancing gastric retention and controlled release. Its lead program was AP-Carbidopa/Levodopa for advanced Parkinson’s disease, which reached Phase III trials. Another candidate was AP-Zaleplon for insomnia.

Therapeutic areas: PsychiatryNeurologyRheumatology
Modalities: Oral drug delivery systemsSmall molecules delivered via proprietary platform
Industry: Biotech

Drug pipeline

3 assets

carbidopa + levodopa

Phase 3

Indications: Parkinson's disease

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Intec Pharma Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intec Pharma Ltd..

Explore the full profile